Amgen publishes Phase 2 study results for Blincyto
Amgen's esults from its Phase 2, open-label ALCANTARA study evaluating the efficacy and safety of BLINCYTO has been published in the Journal of Clinical Oncology. Read More »
Amgen's esults from its Phase 2, open-label ALCANTARA study evaluating the efficacy and safety of BLINCYTO has been published in the Journal of Clinical Oncology. Read More »
Cumberland Pharmaceuticals Inc.'s open label multicenter study, published in Drug Design, Development and Therapy, supports the efficacy and use of Vaprisol Injection for treating hyponatremic patients with severe hepatic impairment. Read More »
Based on 27,564 patient cardiovascular outcomes study, Amgen has established that maximally reducing low-density lipoprotein cholesterol levels with Repatha leads to a further reduction in major cardiovascular events, including heart attacks, strokes and coronary revascularizations. Read More »
Amgen recently announced that the European Commission (EC) granted the company authorization to bring to market Amgevita in all available indications. Read More »
Amgen's data from two studies shows that for appropriate patients in the United States, the majority of prescription claims for PCSK9 inhibitors, such as Repatha (evolocumab), were initially rejected. Read More »
Amgen recently announced the results of the Repatha (evolocumab) cognitive function trial that examined cognitive function for 1,974 patients enrolled in the Repatha cardiovascular outcomes study. Read More »
Amgen recently announced positive data from the Phase 3 '482 study, which is the largest international multiple myeloma trial ever conducted. Read More »
Amgen's positive results from a planned overall survival interim analysis of the Phase 3 head-to-head ENDEAVOR trial. Read More »
Amgen’s recent Phase 3 study of the effects of Repatha on patients who receive apheresis for low-density lipoprotein cholesterol showed a promising reduction in the need for the recurring procedure. Read More »
The results from Amgen’s four-year follow up OSLER-1 study on Repatha, which is so far the longest PCSK9 inhibitor clinical trial, were recently published in JAMA Cardiology. Read More »
Amgen's results of its Repatha (evolocumab) cardiovascular outcomes trial will be released at the American College of Cardiology's 66th Annual Scientific Session, which is set to take place in Washington, D.C. March 17-19. Read More »
Biotech company Amgen submitted an application to the U.S. Food and Drug Administration for Blincyto, a drug used in the treatment of lymphoblastic leukemia, to broaden its uses and treatments. Read More »
Cumberland Pharmaceuticals Inc.'s recent clinical study showed its Caldolor Injection (ibuprofen) to be a safe and effective source of fever reduction in hospitalized pediatric use. Read More »
The U.S. Food and Drug Administration approved Amgen's Parsabiv for the treating of secondary hyperparathyroidism in adults with chronic kidney failure and is administered at dialysis locations throughout the country. Read More »
Charles Holley Jr. has joined the Amgen Board of Directors as a member of the Audit Committee and the Corporate Responsibility and Compliance Committee. Read More »
Biopharmaceutical company Amgen won a major victory in case involving the infringement of two patents held by the company. Read More »
A $1.15 per share dividend was recently declared by Amgen's Board of Directors for the first quarter of next year. Read More »
Amgen presented data from its Phase 3 TOWER study at the 58th Annual Meeting and Exposition of the American Society of Hematology this week in San Diego. Read More »
Amgen will partner with Janssen Biotech to assess the drug combination made up of KYPROLIS, developed by Amgen, and DARZALEX, developed by Janssen, over the course of multiple clinical trials for the treatment of patients who have multiple myeloma. Read More »
Amgen's addition of RepathaA (evolocumab) to optimized statin therapy has resulted in a noteworthy statistical decrease of atherosclerosis in patients who have coronary artery disease. Read More »